The integration of women authorship in ophthalmic research is comparable to that of other medical specialties, but overall women authors are underrepresented when compared with men, according to a study.Philipp W. Kramer, MD, of the Institute of Occupa…
Author: Healio ophthalmology
VIDEO: Steroid challenge predictive of IOP lowering in eyes with fluocinolone implants
CHICAGO — At the American Society of Retina Specialists meeting, Victor H. Gonzalez, MD, summarizes a trial on the real-world use of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) in patients with diabetic macular edema…
Seenu Hariprasad, MD, receives ASRS teaching, mentorship award
Seenu M. Hariprasad, MD, was presented with the Crystal Apple Award by the ASRS Early Career Section for excellence in teaching and mentorship.Hariprasad is the chief of the vitreoretinal service, director of clinical research, and director of fellowsh…
VIDEO: Faricimab shows long-term durability potential as DME treatment
CHICAGO — At the American Society of Retina Specialists meeting, Vrinda S. Hershberger, MD, PhD, discusses her presentation on the anatomical and durability outcomes of faricimab for diabetic macular edema as demonstrated in the BOULEVARD trial.
Patients with glaucoma at higher risk for motor vehicle accidents
Older drivers with glaucoma are involved in automobile accidents at a higher rate than their similarly aged counterparts without glaucoma, according to a study.The prospective 4-year analysis, conducted at Wills Eye Hospital in Philadelphia and present…
Lineage Cell Therapeutics’ Vision Restoration Program awarded NIH grant
Lineage Cell Therapeutics has received a $670,621 Small Business Innovation Research grant from the NIH, according to a press release.The funds are to support the company’s Vision Restoration Program, which generates three-dimensional human retinal tis…
VIDEO: Bi-Blade efficiency compares favorably with single port cutter
CHICAGO — At the American Society of Retina Specialists meeting, Kevin Blinder, MD, discusses his poster presentation comparing the clinical efficiency of the 25-gauge Bi-Blade dual port vitrectomy cutter from Bausch + Lomb with that of a 23-gauge sing…
Kala’s second quarter net loss increases
Kala Pharmaceuticals reported a net loss of $23.8 million, or $0.70 per share, for the second quarter of 2019 compared with a net loss of $14.6 million, or $0.60 per share, for the same period a year ago, according to a press release.Net product revenu…
Quality of sleep associated with glaucoma
Poor sleep parameters, including sleep duration, latency and daytime dysfunction, are associated with glaucoma, either as a risk factor or as a consequence, according to a study.“Experimental models of glaucoma have shown that chronic ocular hypertensi…
Enrollment complete in AcuFocus IC-8 IOL clinical trial
AcuFocus has completed enrollment in a pivotal investigational device exemption study of the IC-8, its small aperture IOL for patients with cataracts, according to a press release.The IC-8, a clear monofocal lens with an embedded mini-ring or pinhole i…
ProQR posts quarterly net loss
ProQR Therapeutics reported a second quarter net loss of 11.7 million euros, or 0.30 euros per share, compared with a net loss of 7.4 million euros, or 0.23 euros per share, in the same quarter of 2018, according to a press release.Research and develop…
Grants awarded to NEI researchers
Two National Eye Institute scientists were awarded grants from the Knights Templar Eye Foundation to research inherited retinal degenerations, according to a press release.Robert Hufnagel, MD, PhD, and Oussama M’Hamdi, PhD, each received $65,000 toward…
Alembic’s generic dorzolamide hydrochloride solution approved
Alembic Pharmaceuticals’ abbreviated new drug application for dorzolamide hydrochloride ophthalmic solution USP 2% has been approved by the FDA, according to a press release.Indicated for the treatment of elevated IOP in ocular hypertension or open-ang…
FDA approves Eylea prefilled syringe
The FDA has approved a chemistry, manufacturing and controls prior-approval supplement for the Eylea injection prefilled syringe, Regeneron announced in a press release.The 2-mg, single-dose, sterilized prefilled Eylea (aflibercept) syringe, which requ…
Iridex revenue increases in second quarter
Iridex reported revenue increased 1.2% to $10.4 million in the second quarter of 2019 compared with $10.3 million during the same period in 2018, according to a press release.Net loss in the second quarter was $2.4 million, or $0.18 per share, compared…
Systems biology approach needed for dry AMD research
Finding treatments for dry age-related macular degeneration requires a large-scale, collaborative, systems biology approach.Dry AMD, which currently has no treatment options, is a leading cause of blindness in people aged 65 years and older.A report pu…
ProQR’s retinitis pigmentosa candidate gets investigational NDA clearance
The FDA has cleared an investigational new drug application for QR-1123, an investigational oligonucleotide treatment candidate for vision loss with autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin gene, according to a …
BioTime rebrands as Lineage Cell Therapeutics
BioTime has changed its name to Lineage Cell Therapeutics to better reflect its commitment to becoming a leading cell therapy company, according to a press release.“It has been less than 1 year since I joined the company, and I’m excited that we have l…
EyePoint reports lower net loss for second quarter
EyePoint Pharmaceuticals reported a second quarter net loss of $11.5 million, or $0.11 per share, compared with a net loss of $34.4 million, or $0.62 per share, in the same quarter of 2018, according to a press release.Total quarterly revenue was $7.2 …
Read OSN’s Aug. 10 publication exclusives online
The cover story in the Aug. 10, 2019, issue of Ocular Surgery News focused on new IOL technology. Here are some of the issue’s publication exclusives: Cover StoryNew frontiers in IOL technology aim at flexible, customized solutionsDespite decades of tr…